- Conditions
- Chondral Defect, Osteochondritis Dissecans (OCD), Articular Cartilage Defect, Articular Cartilage Disorder of Knee
- Interventions
- MACI, microfracture
- Biological · Procedure
- Lead sponsor
- Vericel Corporation
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 15
- States / cities
- Palo Alto, California • Sacramento, California • New Orleans, Louisiana + 10 more
Location Directory
Clinical trials in Baltimore, Maryland
This page shows live ClinicalTrials.gov search results for Baltimore, Maryland, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
13749
Shown on this page
12
Current sort
Recently updated
Location scope
Baltimore, MD
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 565–576 of 13,749 matching trials in Baltimore, MD.
Live ClinicalTrials.gov results.
Institutions in Baltimore
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Carcinoma, Non-small-Cell Lung
- Interventions
- Amivantamab, Lazertinib, Carboplatin, Pemetrexed, Direct Oral Anticoagulant (DOAC), Low Molecular Weight Heparin (LMWH)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 26
- States / cities
- La Jolla, California • Orange, California • Stanford, California + 21 more
- Conditions
- Arthritis, Psoriatic
- Interventions
- Guselkumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 453 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 50
- States / cities
- Mountain Brook, Alabama • Avondale, Arizona • Flagstaff, Arizona + 46 more
- Conditions
- Hemolytic Disease of the Fetus and Newborn
- Interventions
- Nipocalimab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 22
- States / cities
- La Jolla, California • Los Angeles, California • Sacramento, California + 19 more
- Conditions
- Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Lutetium Lu 177 Vipivotide Tetraxetan, Biospecimen Collection, Patient Monitoring, Computed Tomography, Bone Scan, PSMA PET Scan, MRI, Questionnaire Administration
- Drug · Procedure · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,524 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 142
- States / cities
- Anchorage, Alaska • Bakersfield, California • Irvine, California + 117 more
- Conditions
- Advanced or Metastatic Colorectal Cancer
- Interventions
- Amivantamab IV, Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan, Amivantamab
- Biological
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 9 more
- Conditions
- Multiple Myeloma
- Interventions
- Teclistamab, Daratumumab, Lenalidomide, Dexamethasone, Talquetamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2033
- U.S. locations
- 67
- States / cities
- Gilbert, Arizona • Tucson, Arizona • Clovis, California + 53 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- Tobemstomig, Tiragolumab, Pembrolizumab, Axitinib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Orange, California • Atlanta, Georgia + 3 more
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Amivantamab, Pembrolizumab, Paclitaxel, Carboplatin
- Biological · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 287 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 15
- States / cities
- La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 12 more
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Amivantamab, Pembrolizumab, Carboplatin, 5-Flurouracil, Cisplatin
- Biological · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 51
- States / cities
- Chandler, Arizona • Tucson, Arizona • Fullerton, California + 44 more
- Conditions
- Colon Adenocarcinoma, Colorectal Adenocarcinoma, Rectal Adenocarcinoma, Stage I Colon Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage I Rectal Cancer AJCC v8, Stage II Colon Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage II Rectal Cancer AJCC v8, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8
- Interventions
- Biospecimen Collection, Genetic Testing, Communication Intervention, Survey Administration
- Procedure · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4,186 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2032
- U.S. locations
- 358
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 268 more
- Conditions
- Multiple Myeloma
- Interventions
- Cevostamab, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 9
- States / cities
- Aurora, Colorado • Jacksonville, Florida • Baltimore, Maryland + 5 more